Literature DB >> 10338335

Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression.

T Vlaykova1, P Laurila, T Muhonen, M Hahka-Kemppinen, A Jekunen, K Alitalo, S Pyrhönen.   

Abstract

Tumour angiogenesis is essential for tumour growth and metastasis. Several lines of evidence indicate that vascular endothelial growth factor (VEGF) is a major regulator both of physiological and pathological angiogenesis. In this study we assessed the blood vessel density and VEGF expression of 94 melanoma metastases of 70 patients by immunohistochemistry, utilizing antibodies against human platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) and VEGF. The number of blood vessels ranged from 4 to 131 vessels/high power field (HPF), with a mean value of 32 vessels/HPF (+/-21) and a median of 29 vessels/ HPF. Survival since diagnosis of the primary disease and from the start of chemoimmunotherapy, as well as the disease-free survival period, was significantly shorter in the high vascularity group of patients compared with the low vascularity group (P< 0.05 and P< 0.01, respectively). A high overall expression of VEGF in the metastatic melanoma samples was observed. The degree of VEGF expression appeared to have a strong association with the blood vessel density (P= 0.017). This study demonstrates the clinical role of tumour vascularity in the prognosis of patients with metastatic melanoma. In addition, the strong association between vascularity and VEGF expression suggests a crucial role for this growth factor in the neovascularization of metastatic melanoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10338335     DOI: 10.1097/00008390-199902000-00008

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  16 in total

Review 1.  Angiogenesis and melanoma.

Authors:  J P Dutcher
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

2.  Angiogenesis and melanoma - from basic science to clinical trials.

Authors:  Maxine Sylvia Emmett; Daemon Dewing; Rowan Oliver Pritchard-Jones
Journal:  Am J Cancer Res       Date:  2011-08-08       Impact factor: 6.166

3.  ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).

Authors:  Ronald S Go; Sandra J Lee; Donghoon Shin; Steven M Callister; Dean A Jobe; Robert M Conry; Ahmad A Tarhini; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2013-10-11       Impact factor: 12.531

4.  Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells.

Authors:  Daniel Gioeli; Chelsi J Snow; Michael B Simmers; Stephen A Hoang; Robert A Figler; J Ashe Allende; Devin G Roller; J Thomas Parsons; Julia D Wulfkuhle; Emanuel F Petricoin; Todd W Bauer; Brian R Wamhoff
Journal:  Lab Chip       Date:  2019-03-27       Impact factor: 6.799

5.  Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.

Authors:  Kriti Mittal; Henry Koon; Paul Elson; Pierre Triozzi; Afshin Dowlati; Helen Chen; Ernest C Borden; Brian I Rini
Journal:  Cancer Biol Ther       Date:  2014-05-19       Impact factor: 4.742

6.  BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

Authors:  Kevin B Kim; Jeffrey A Sosman; John P Fruehauf; Gerald P Linette; Svetomir N Markovic; David F McDermott; Jeffrey S Weber; Hoa Nguyen; Peter Cheverton; Daniel Chen; Amy C Peterson; William E Carson; Steven J O'Day
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

7.  Doppler ultrasound flowmetry predicts 15 year outcome in patients with skin melanoma.

Authors:  Anurag Srivastava; John P Woodcock; Robert E Mansel; David J T Webster; Peter Laidler; Leslie E Hughes; Alok Dwivedi
Journal:  Indian J Surg       Date:  2012-01-21       Impact factor: 0.656

8.  Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

Authors:  Janice M Mehnert; Mary M McCarthy; Lucia Jilaveanu; Keith T Flaherty; Saadia Aziz; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Hum Pathol       Date:  2009-12-11       Impact factor: 3.466

Review 9.  A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?

Authors:  E Hormbrey; P Gillespie; K Turner; C Han; A Roberts; D McGrouther; A L Harris
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

10.  Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.

Authors:  Soheil S Dadras; Thomas Paul; Jennifer Bertoncini; Lawrence F Brown; Alona Muzikansky; David G Jackson; Ulf Ellwanger; Claus Garbe; Martin C Mihm; Michael Detmar
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.